H Y Win1, M Acevedo-Duncan. 1. Department of Chemistry, University of South Florida, Tampa, Florida, USA.
Abstract
UNLABELLED: Prostate cancer is one of the leading causes of death among men in the USA. OBJECTIVE: In this study, we investigated the role of atypical protein kinase C-iota (PKC-iota) in androgen independent prostate DU-145 carcinoma cellscompared to transformed non-malignant prostate RWPE-1 cells. MATERIALS AND METHODS: Western blotting and immunoprecipitations demonstrated that PKC-iotaisassociated with cyclin-dependent kinase activating kinase (CAK/Cdk7) in RWPE-1 cells, but not in DU-145 cells. RESULTS: Treatment of prostate RWPE-1 cells with PKC-iota silencing RNA (siRNA) decreased cell viability,cell-cycle accumulation at G2/M phase, and phosphorylation of Cdk7 and Cdk2. In addition, PKC-iota siRNA treatment caused less phosphorylation ofBad at ser-155, ser-136, and greater Bad/Bcl-xL heterodimerization, leading to apoptosis. In DU-145 cells, PKC-iota was anti-apoptotic and was required for cell survival. Treatment with PKC-iota siRNA blocked increase in cell number, and inhibited G1/S transition by accumulation of cells in G0/G1phase. In addition to cell-cycle arrest, both RWPE-1 and DU-145 cells underwent apoptosis due to mitochondrial dysfunction and apoptosis cascades, such as release of cytochrome c,activation of caspase-7, and poly (ADP-ribose)polymerase (PARP) cleavage. CONCLUSION: Our results suggest that PKC-iota is required for cell survival in both transformed non-malignant prostate RWPE-1 cells and androgen-independent malignant prostate DU-145 cells, whereas suppressing PKC-iota lead to apoptosis in DU-145 prostate cells.
UNLABELLED: Prostate cancer is one of the leading causes of death among men in the USA. OBJECTIVE: In this study, we investigated the role of atypical protein kinase C-iota (PKC-iota) in androgen independent prostate DU-145 carcinoma cellscompared to transformed non-malignant prostate RWPE-1 cells. MATERIALS AND METHODS: Western blotting and immunoprecipitations demonstrated that PKC-iotaisassociated with cyclin-dependent kinase activating kinase (CAK/Cdk7) in RWPE-1 cells, but not in DU-145 cells. RESULTS: Treatment of prostate RWPE-1 cells with PKC-iota silencing RNA (siRNA) decreased cell viability,cell-cycle accumulation at G2/M phase, and phosphorylation of Cdk7 and Cdk2. In addition, PKC-iota siRNA treatment caused less phosphorylation ofBad at ser-155, ser-136, and greater Bad/Bcl-xL heterodimerization, leading to apoptosis. In DU-145 cells, PKC-iota was anti-apoptotic and was required for cell survival. Treatment with PKC-iota siRNA blocked increase in cell number, and inhibited G1/S transition by accumulation of cells in G0/G1phase. In addition to cell-cycle arrest, both RWPE-1 and DU-145 cells underwent apoptosis due to mitochondrial dysfunction and apoptosis cascades, such as release of cytochrome c,activation of caspase-7, and poly (ADP-ribose)polymerase (PARP) cleavage. CONCLUSION: Our results suggest that PKC-iota is required for cell survival in both transformed non-malignant prostate RWPE-1 cells and androgen-independent malignant prostate DU-145 cells, whereas suppressing PKC-iota lead to apoptosis in DU-145 prostate cells.
Authors: K Kikuchi; A Soundararajan; L A Zarzabal; C R Weems; L D Nelon; S T Hampton; J E Michalek; B P Rubin; A P Fields; C Keller Journal: Oncogene Date: 2012-02-20 Impact factor: 9.867
Authors: Wishrawana S Ratnayake; André H Apostolatos; David A Ostrov; Mildred Acevedo-Duncan Journal: Int J Oncol Date: 2017-09-22 Impact factor: 5.650
Authors: Hyoung Kyu Kim; Sung Woo Cho; Hye Jin Heo; Seung Hun Jeong; Min Kim; Kyung Soo Ko; Byoung Doo Rhee; Natalia P Mishchenko; Elena A Vasileva; Sergey A Fedoreyev; Valentin A Stonik; Jin Han Journal: Mar Drugs Date: 2018-06-02 Impact factor: 5.118
Authors: André H Apostolatos; Christopher A Apostolatos; Wishrawana S Ratnayake; Anthony Neuger; Samer Sansil; Marie Bourgeois; Mildred Acevedo-Duncan Journal: Anticancer Drugs Date: 2019-01 Impact factor: 2.248